DK0948495T3 - Aryl- og heteroarylsubstitueret, kondenseret pyrrol som antiinflammatoriske midler - Google Patents

Aryl- og heteroarylsubstitueret, kondenseret pyrrol som antiinflammatoriske midler

Info

Publication number: DK0948495T3
Authority: DK; Denmark
Prior art keywords: compounds; useful; prophylaxis; aryl; treatment
Prior art date: 1996-11-19

Application number

DK97947617T

Other languages

English (en)

Inventor

Jeffery A Zablocki

Eugene Tarlton Jr

James P Rizzi

Nathan B Mantlo

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-11-19

Filing date

1997-11-18

Publication date

2004-06-01

1997-11-18 Application filed by Amgen Inc filed Critical Amgen Inc

2004-06-01 Application granted granted Critical

2004-06-01 Publication of DK0948495T3 publication Critical patent/DK0948495T3/da

Links

KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 title 2
229940121363 anti-inflammatory agent Drugs 0.000 title 1
239000002260 anti-inflammatory agent Substances 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 5
238000000034 method Methods 0.000 abstract 4
201000010099 disease Diseases 0.000 abstract 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
238000011321 prophylaxis Methods 0.000 abstract 3
238000011282 treatment Methods 0.000 abstract 3
206010061218 Inflammation Diseases 0.000 abstract 2
206010012601 diabetes mellitus Diseases 0.000 abstract 2
230000004054 inflammatory process Effects 0.000 abstract 2
239000000543 intermediate Substances 0.000 abstract 2
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract 1
-1 IL-1beta Proteins 0.000 abstract 1
108090001005 Interleukin-6 Proteins 0.000 abstract 1
102000004890 Interleukin-8 Human genes 0.000 abstract 1
108090001007 Interleukin-8 Proteins 0.000 abstract 1
108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
125000001072 heteroaryl group Chemical group 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
150000003233 pyrroles Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Oncology (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Neurology (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Cardiology (AREA)
Obesity (AREA)
Transplantation (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)

DK97947617T 1996-11-19 1997-11-18 Aryl- og heteroarylsubstitueret, kondenseret pyrrol som antiinflammatoriske midler DK0948495T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US3120796P	1996-11-19	1996-11-19
PCT/US1997/021344 WO1998022457A1 (en)	1996-11-19	1997-11-18	Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents

Publications (1)

Publication Number	Publication Date
DK0948495T3 true DK0948495T3 (da)	2004-06-01

Family

ID=21858180

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK97947617T DK0948495T3 (da)	1996-11-19	1997-11-18	Aryl- og heteroarylsubstitueret, kondenseret pyrrol som antiinflammatoriske midler

Country Status (15)

Country	Link
US (3)	US6180643B1 (da)
EP (1)	EP0948495B1 (da)
JP (1)	JP2001506980A (da)
KR (1)	KR20000057137A (da)
CN (1)	CN1246856A (da)
AT (1)	ATE264318T1 (da)
AU (1)	AU734841B2 (da)
CA (1)	CA2271767A1 (da)
DE (1)	DE69728688T2 (da)
DK (1)	DK0948495T3 (da)
ES (1)	ES2215242T3 (da)
HU (1)	HUP9903330A2 (da)
IL (1)	IL129928A0 (da)
PT (1)	PT948495E (da)
WO (1)	WO1998022457A1 (da)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100378937B1 (ko)	1997-10-20	2003-05-09	에프. 호프만-라 로슈 아게	바이사이클릭 키나아제 억제제
EP1037639A4 (en)	1997-12-19	2002-04-17	Smithkline Beecham Corp	HETEROARYL-SUBSTITUTED IMIDAZOLE COMPOUNDS, THEIR PHARMACEUTICAL COMPOSITIONS AND USES
US6858617B2 (en)	1998-05-26	2005-02-22	Smithkline Beecham Corporation	Substituted imidazole compounds
ES2221426T3 (es) *	1998-08-20	2004-12-16	Smithkline Beecham Corporation	Nuevos compuestos de triazol sustituidos.
WO2000021963A1 (en) *	1998-10-13	2000-04-20	Smithkline Beecham Corporation	Il-8 receptor antagonists
DE19847823A1 (de) *	1998-10-16	2000-04-20	Aventis Pharma Gmbh	Substituierte Thiadiazolsulfonamide
WO2000025791A1 (en)	1998-11-04	2000-05-11	Smithkline Beecham Corporation	Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
US6686374B1 (en) *	1999-08-12	2004-02-03	Nps Allelix Corp.	Azaindoles having serotonin receptor affinity
US6440993B1 (en)	1999-10-12	2002-08-27	Smithkline Beecham Corporation	IL-8 receptor antagonists
DE19951360A1 (de)	1999-10-26	2001-05-03	Aventis Pharma Gmbh	Substituierte Indole
AU7922900A (en) *	1999-10-27	2001-05-08	Novartis Ag	Thiazole and imidazo (4,5-b) pyridine compounds and their pharmaceutical use
AU1782301A (en)	1999-11-23	2001-06-04	Smithkline Beecham Corporation	3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p39 kinase inhibitors
AU1783201A (en)	1999-11-23	2001-06-04	Smithkline Beecham Corporation	3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
US6759410B1 (en)	1999-11-23	2004-07-06	Smithline Beecham Corporation	3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
PT1175214E (pt)	1999-12-08	2005-04-29	Pharmacia Corp	Composicoes de inibidor de ciclo-oxigenase-2 com um inicio rapido do seu efito terapeutico
GB9930698D0 (en) *	1999-12-24	2000-02-16	Rhone Poulenc Rorer Ltd	Chemical compounds
HRP20020547B1 (hr) *	1999-12-24	2011-06-30	Aventis Pharma Limited	Azaindoli
JP2003522191A (ja) *	2000-02-11	2003-07-22	アストラゼネカ・アクチエボラーグ	ケモカイン受容体活性のモジュレーターとしてのピリミジン化合物およびそれらの使用
US7235551B2 (en)	2000-03-02	2007-06-26	Smithkline Beecham Corporation	1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
AU2001259707A1 (en)	2000-06-14	2001-12-24	Warner Lambert Company	6,5-fused bicyclic heterocycles
GB0112348D0 (en) *	2001-05-19	2001-07-11	Smithkline Beecham Plc	Compounds
GB0115109D0 (en)	2001-06-21	2001-08-15	Aventis Pharma Ltd	Chemical compounds
US20050101563A1 (en) *	2001-08-14	2005-05-12	Pharmacia Corporation	Method and compositions for the treatment and prevention of pain and inflammation
US20030144219A1 (en)	2001-11-15	2003-07-31	Phinney Stephen Dodge	Formulations and methods for treatment or amelioration of inflammatory conditions
JP2003183283A (ja) *	2001-12-18	2003-07-03	Takeda Chem Ind Ltd	縮合インドール化合物、その製造法および用途
AR039241A1 (es) *	2002-04-04	2005-02-16	Biogen Inc	Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
US7393862B2 (en) *	2002-05-17	2008-07-01	Celgene Corporation	Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
AU2003245989A1 (en)	2002-07-09	2004-01-23	Boehringer Ingelheim Pharma Gmbh And Co. Kg	Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
EP1388541A1 (en)	2002-08-09	2004-02-11	Centre National De La Recherche Scientifique (Cnrs)	Pyrrolopyrazines as kinase inhibitors
SE0202463D0 (sv) *	2002-08-14	2002-08-14	Astrazeneca Ab	Novel compounds
UA80295C2 (en) *	2002-09-06	2007-09-10	Biogen Inc	Pyrazolopyridines and using the same
SE0300908D0 (sv)	2003-03-31	2003-03-31	Astrazeneca Ab	Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
PT1696920E (pt)	2003-12-19	2015-01-14	Plexxikon Inc	Compostos e métodos para o desenvolvimento de moduladores de ret
US7498342B2 (en)	2004-06-17	2009-03-03	Plexxikon, Inc.	Compounds modulating c-kit activity
US7781478B2 (en)	2004-07-14	2010-08-24	Ptc Therapeutics, Inc.	Methods for treating hepatitis C
EP1797054A2 (en) *	2004-08-02	2007-06-20	OSI Pharmaceuticals, Inc.	Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
US20060035893A1 (en)	2004-08-07	2006-02-16	Boehringer Ingelheim International Gmbh	Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
EP1632491A1 (en) *	2004-08-30	2006-03-08	Laboratorios Del Dr. Esteve, S.A.	Substituted indole compounds and their use as 5-HT6 receptor modulators
PE20060777A1 (es)	2004-12-24	2006-10-06	Boehringer Ingelheim Int	Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
WO2007002325A1 (en) *	2005-06-22	2007-01-04	Plexxikon, Inc.	Pyrrolo[2,3-b] pyridine derivatives as protein kinase inhibitors
SI1979314T1 (sl) *	2006-01-24	2013-02-28	Eli Lilly And Company	Indol sulfonamidni modulatorji progesteronskih receptorjev
MX2008010481A (es)	2006-02-17	2008-12-19	Memory Pharm Corp	Compuestos que tienen afinado para el receptor f-ht6.
DE102006012617A1 (de) *	2006-03-20	2007-09-27	Merck Patent Gmbh	4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
CL2007002617A1 (es)	2006-09-11	2008-05-16	Sanofi Aventis	Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
WO2008063888A2 (en)	2006-11-22	2008-05-29	Plexxikon, Inc.	Compounds modulating c-fms and/or c-kit activity and uses therefor
EP1992344A1 (en)	2007-05-18	2008-11-19	Institut Curie	P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
SG183036A1 (en)	2007-07-17	2012-08-30	Plexxikon Inc	Compounds and methods for kinase modulation, and indications therefor
BRPI0815154B1 (pt)	2007-08-17	2024-01-30	Lg Chem, Ltd	Compostos de indol, composição, e, método de preparação da mesma
WO2009042092A1 (en) *	2007-09-25	2009-04-02	Merck & Co., Inc.	2-aryl or heteroaryl indole derivatives
DE102008052943A1 (de) *	2008-10-23	2010-04-29	Merck Patent Gmbh	Azaindolderivate
AU2010232670B2 (en)	2009-04-03	2015-07-09	F. Hoffmann-La Roche Ag	Propane- I-sulfonic acid {3- [5- (4 -chloro-phenyl) -1H-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof
EP2245936A1 (en)	2009-04-27	2010-11-03	Bayer CropScience AG	Use of 4-aza indole derivatives for the reduction of mycotoxin contamination
CN102471345A (zh)	2009-07-15	2012-05-23	雅培制药有限公司	激酶的吡咯并吡嗪抑制剂
CA2767089A1 (en)	2009-07-15	2011-01-20	Abbott Laboratories	Pyrrolopyridine inhibitors of kinases
MX2012004914A (es)	2009-10-30	2012-08-15	Massachusetts Inst Technology	Compuestos de 2-aminoindol y metodos para el tratamiento de la malaria.
ES2633317T3 (es)	2009-11-06	2017-09-20	Plexxikon, Inc.	Compuestos y métodos para la modulación de quinasas, e indicaciones para ello
US8222416B2 (en) *	2009-12-14	2012-07-17	Hoffmann-La Roche Inc.	Azaindole glucokinase activators
CN102939282B (zh) *	2010-04-16	2015-12-02	Ac免疫有限公司	用于治疗与淀粉状蛋白或淀粉状蛋白样蛋白有关的疾病的化合物
US9512111B2 (en)	2010-11-08	2016-12-06	Lycera Corporation	N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease
EP2796456A1 (en)	2010-12-09	2014-10-29	Amgen Inc.	Bicyclic compounds as Pim inhibitors
CN103517710B (zh)	2011-02-07	2017-05-31	普莱希科公司	用于激酶调节的化合物
TWI558702B (zh)	2011-02-21	2016-11-21	普雷辛肯公司	醫藥活性物質的固態形式
AU2012230890A1 (en)	2011-03-22	2013-09-26	Amgen Inc.	Azole compounds as Pim inhibitors
PL2800737T3 (pl)	2012-01-06	2020-11-02	Novus International Inc.	Środki powierzchniowo czynne na bazie sulfotlenku
US9284294B2 (en)	2012-02-09	2016-03-15	Novus International, Inc.	Functionalized polymer compositions
CA2871514C (en)	2012-05-08	2020-08-25	Merck Sharp & Dohme Corp.	Tetrahydronaphthyridine and related bicyclic compounds for inhibition of ror.gamma.activity and the treatment of disease
WO2013169864A2 (en)	2012-05-08	2013-11-14	Lycera Corporation	TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE
US9150570B2 (en)	2012-05-31	2015-10-06	Plexxikon Inc.	Synthesis of heterocyclic compounds
PL2871973T3 (pl)	2012-07-12	2019-02-28	Novus International Inc.	Kompozycje matrycy i warstwy do ochrony środków bioaktywnych
FR3001219A1 (fr) *	2013-01-22	2014-07-25	Centre Nat Rech Scient	Inhibiteurs de kinases
WO2015095788A1 (en)	2013-12-20	2015-06-25	Merck Sharp & Dohme Corp.	2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
US9809561B2 (en)	2013-12-20	2017-11-07	Merck Sharp & Dohme Corp.	Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
US9783511B2 (en)	2013-12-20	2017-10-10	Lycera Corporation	Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease
EP3110429A4 (en)	2014-02-27	2018-02-21	Lycera Corporation	Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma & related therapeutic methods
AU2015256190B2 (en)	2014-05-05	2019-08-15	Lycera Corporation	Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
WO2015171558A2 (en)	2014-05-05	2015-11-12	Lycera Corporation	BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
WO2016040570A2 (en)	2014-09-12	2016-03-17	Children's Medical Center Corporation	Dietary emulsion formulations and methods for using the same
JP2018510135A (ja)	2015-02-11	2018-04-12	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	ＲＯＲγＴ阻害剤としての置換ピラゾール化合物及びその使用
JP2018515491A (ja)	2015-05-05	2018-06-14	リセラ・コーポレイションＬｙｃｅｒａＣｏｒｐｏｒａｔｉｏｎ	ＲＯＲγの作動薬及び疾患の療法として使用するジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジンスルホンアミド及び関連化合物
EP3307738B1 (en)	2015-06-11	2022-04-20	The Regents of the University of Michigan	Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of rory and the treatment of disease
CA3002853A1 (en)	2015-10-27	2017-05-04	Merck Sharp & Dohme Corp.	Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof
CA3002850A1 (en)	2015-10-27	2017-05-04	Merck Sharp & Dohme Corp.	Substituted indazole compounds as rorgammat inhibitors and uses thereof
WO2017075178A1 (en)	2015-10-27	2017-05-04	Merck Sharp & Dohme Corp.	SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
AU2016353076A1 (en)	2015-11-12	2018-05-10	Novus International Inc.	Sulfur-containing compounds as solvents
TWI674260B (zh)	2017-02-01	2019-10-11	德商菲尼克斯製藥股份有限公司	芳基烴受體(AhR)調節劑化合物
TWI752155B (zh) *	2017-02-01	2022-01-11	德商菲尼克斯製藥股份有限公司	芳香烴受體(AhR)調節劑化合物
US10584306B2 (en)	2017-08-11	2020-03-10	Board Of Regents Of The University Of Oklahoma	Surfactant microemulsions
TWI748194B (zh)	2018-06-28	2021-12-01	德商菲尼克斯Ｆｘｒ有限責任公司	含有雙環核心部分之新穎lxr調節劑
IL282021B2 (en)	2018-10-05	2025-04-01	Annapurna Bio Inc	Compounds and compositions for treating conditions associated with APJ receptor activity
KR20250097400A (ko) *	2023-12-21	2025-06-30	한미약품 주식회사	Yap-tead 상호작용 억제를 위한 신규한 헤테로비시클릭 화합물 및 이를 포함하는 약학적 조성물
CN118994121B (zh) *	2024-07-29	2025-11-25	大连理工大学	一种3-（2-三氟甲基-3-芳基-4h-色烯-4-基）-1h-吲哚衍生物、制备方法及应用
CN119613409A (zh) *	2024-12-05	2025-03-14	浙江工业大学	吡咯并[2,3-d]嘧啶衍生物及其在制备抗炎药物中的应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3420838A (en)	1965-12-20	1969-01-07	Upjohn Co	2,3-bis(p-(omega-aminoalkoxy)phenyl)-indoles
US3429874A (en) *	1966-12-22	1969-02-25	Schering Corp	1-polyhalogenoalkyl-2-oxo-1,3-dihydro-2h-1,4-benzodiazepines
BE720261A (da) *	1967-09-01	1969-02-28
DE1795061A1 (de)	1968-08-05	1972-02-24	Rhein Pharma Arzneimittel Gmbh	Verfahren zur Herstellung von 3-Pyridyl(4)-indolen
US3551567A (en)	1968-08-07	1970-12-29	American Cyanamid Co	Compositions containing indolylpyridinium salts and method of use
US3565912A (en) *	1969-01-27	1971-02-23	Upjohn Co	5-lower-alkanoyl-2,3-bis(p-methoxyphenyl)indoles
US3654308A (en)	1969-01-27	1972-04-04	Upjohn Co	2 3-bis(p-methoxyphenyl)-indole-5-carboxylic acid derivatives
US3929807A (en)	1971-05-10	1975-12-30	Ciba Geigy Corp	2-Substituted-4(5)-(aryl)-5(4)-(2,3 or -4-pyridyl)-imidazoles
DE2909779A1 (de)	1979-03-13	1980-09-18	Thomae Gmbh Dr K	Neue indolderivate, deren herstellung und deren verwendung als arzneimittel
US4794114A (en)	1986-08-19	1988-12-27	Smithkline Beckman Corporation	Inhibition of interleukin-1 production by monocytes and/or macrophages
AU5921890A (en)	1989-06-13	1991-01-08	Smithkline Beecham Corporation	Monokine activity interference
KR920702621A (ko)	1989-06-13	1992-10-06	스튜어트 알. 슈터	단핵세포 및/또는 마크로파지에 의한 인터루킨-1 또는 종양회사인자 생성의 억제
JPH06503349A (ja)	1990-12-13	1994-04-14	スミスクライン・ビーチャム・コーポレイション	新規ｃｓａｉｄｓ
AU9137591A (en)	1990-12-13	1992-07-08	Smithkline Beecham Corporation	Novel csaids
WO1992012154A1 (en)	1990-12-31	1992-07-23	Fujisawa Pharmaceutical Co., Ltd.	Imidazotriazine derivatives
GB9121727D0 (en)	1991-10-14	1991-11-27	Ici Plc	Heterocyclic compounds
MX9300141A (es)	1992-01-13	1994-07-29	Smithkline Beecham Corp	Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
FR2687402B1 (fr)	1992-02-14	1995-06-30	Lipha	Nouveaux azaindoles, procedes de preparation et medicaments les contenant.
PL175327B1 (pl)	1992-04-03	1998-12-31	Upjohn Co	Dwupierścieniowe heterocykliczne aminy
US5502187A (en)	1992-04-03	1996-03-26	The Upjohn Company	Pharmaceutically active bicyclic-heterocyclic amines
DE69214633T2 (de)	1992-06-19	1997-05-22	Agfa Gevaert Nv	Thermisch übertragbare fluoreszierende Verbindungen
ZA939516B (en)	1992-12-22	1994-06-06	Smithkline Beecham Corp	Endothelin receptor antagonists
JP3119758B2 (ja)	1993-02-24	2000-12-25	日清製粉株式会社	７−アザインドール誘導体及びこれを有効成分とする抗潰瘍薬
JP3465827B2 (ja)	1993-02-24	2003-11-10	株式会社日清製粉グループ本社	アザインドール誘導体およびこれを有効成分とする抗潰瘍薬
US5593992A (en)	1993-07-16	1997-01-14	Smithkline Beecham Corporation	Compounds
GB2282595A (en) *	1993-08-25	1995-04-12	Yamanouchi Pharma Co Ltd	Benzodiazepine derivatives
ES2109796T3 (es) *	1994-05-03	1998-01-16	Ciba Geigy Ag	Derivados de pirrolopirimidilo con efecto antiproliferante.
JPH10510510A (ja)	1994-06-09	1998-10-13	スミスクライン・ビーチャム・コーポレイション	エンドセリン受容体拮抗物質
US5550132A (en)	1994-06-22	1996-08-27	University Of North Carolina	Hydroxyalkylammonium-pyrimidines or purines and nucleoside derivatives, useful as inhibitors of inflammatory cytokines
US5620999A (en)	1994-07-28	1997-04-15	Weier; Richard M.	Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5521213A (en) *	1994-08-29	1996-05-28	Merck Frosst Canada, Inc.	Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
PL321292A1 (en)	1995-01-12	1997-11-24	Smithkline Beecham Corp	Novel xchemical compounds
CA2224435C (en)	1995-07-06	2008-08-05	Novartis Ag	Pyrrolopyrimidines and processes for the preparation thereof
WO1997016442A1 (en)	1995-10-31	1997-05-09	Merck & Co., Inc.	Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
JPH1035267A (ja) *	1996-07-22	1998-02-10	Denso Corp	車両用屋上装着型冷房装置
WO1998047899A1 (en)	1997-04-24	1998-10-29	Ortho-Mcneil Corporation, Inc.	Substituted pyrrolopyridines useful in the treatment of inflammatory diseases
KR100378937B1 (ko) *	1997-10-20	2003-05-09	에프. 호프만-라 로슈 아게	바이사이클릭 키나아제 억제제

1997
- 1997-11-18 DK DK97947617T patent/DK0948495T3/da active
- 1997-11-18 US US09/269,600 patent/US6180643B1/en not_active Expired - Fee Related
- 1997-11-18 DE DE69728688T patent/DE69728688T2/de not_active Expired - Fee Related
- 1997-11-18 KR KR1019990704405A patent/KR20000057137A/ko not_active Ceased
- 1997-11-18 WO PCT/US1997/021344 patent/WO1998022457A1/en not_active Ceased
- 1997-11-18 AU AU52659/98A patent/AU734841B2/en not_active Ceased
- 1997-11-18 CA CA002271767A patent/CA2271767A1/en not_active Abandoned
- 1997-11-18 PT PT97947617T patent/PT948495E/pt unknown
- 1997-11-18 ES ES97947617T patent/ES2215242T3/es not_active Expired - Lifetime
- 1997-11-18 JP JP52391498A patent/JP2001506980A/ja active Pending
- 1997-11-18 IL IL12992897A patent/IL129928A0/xx unknown
- 1997-11-18 CN CN97181372A patent/CN1246856A/zh active Pending
- 1997-11-18 AT AT97947617T patent/ATE264318T1/de not_active IP Right Cessation
- 1997-11-18 EP EP97947617A patent/EP0948495B1/en not_active Expired - Lifetime
- 1997-11-18 HU HU9903330A patent/HUP9903330A2/hu unknown
2000
- 2000-08-23 US US09/644,102 patent/US6440973B1/en not_active Expired - Fee Related
2002
- 2002-06-18 US US10/175,182 patent/US6605634B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
HUP9903330A2 (hu)	2000-03-28
DE69728688T2 (de)	2004-08-19
CA2271767A1 (en)	1998-05-28
US6605634B2 (en)	2003-08-12
ATE264318T1 (de)	2004-04-15
AU734841B2 (en)	2001-06-21
US6440973B1 (en)	2002-08-27
DE69728688D1 (de)	2004-05-19
IL129928A0 (en)	2000-02-29
WO1998022457A1 (en)	1998-05-28
JP2001506980A (ja)	2001-05-29
EP0948495B1 (en)	2004-04-14
US6180643B1 (en)	2001-01-30
EP0948495A1 (en)	1999-10-13
AU5265998A (en)	1998-06-10
US20030096819A1 (en)	2003-05-22
ES2215242T3 (es)	2004-10-01
PT948495E (pt)	2004-08-31
CN1246856A (zh)	2000-03-08
KR20000057137A (ko)	2000-09-15

Publication	Publication Date	Title
DK0948495T3 (da)	2004-06-01	Aryl- og heteroarylsubstitueret, kondenseret pyrrol som antiinflammatoriske midler
ATE366722T1 (de)	2007-08-15	Substituierte pyridin-derivate als entzündungshemmende mittel
DK1448564T3 (da)	2006-08-21	Substituerede indolizinlignende forbindelser og fremgangsmåder til anvendelse
DK1042293T3 (da)	2008-07-14	Substituerede pyridin- og pyridazinforbindelser og deres farmaceutiske anvendelse
WO1998024782A3 (en)	1998-08-27	Substituted pyrimidine compounds and their use
WO1998024780A3 (en)	1998-07-30	Substituted pyrimidinone and pyridinone compounds and their use
BG102241A (bg)	1998-12-30	Инхибитори на клетъчна адхезия
PT1309589E (pt)	2006-05-31	Compostos de ureia e metodos de utilizacao
EA200300293A1 (ru)	2003-08-28	Противовоспалительные конденсированные пирролокарбазолы
DE60225556D1 (de)	2008-04-24	Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
MX9703546A (es)	1997-08-30	Benzotiazepinas hipolipidemicas.
FI973087A7 (fi)	1997-09-22	Soluadheesion inhibiittoreita
FI20115753L (fi)	2011-07-15	Farmaseuttisia koostumuksia IL-6:n tuoton aiheuttamien sairauksien hoitoon
NO20060278L (no)	2006-03-15	Piperazinderivater og fremgangsmater for anvendelse
MXPA05010883A (es)	2006-01-23	Derivados de amina ciclica y su uso en el tratamiento de trastornos inflamatorios relacionados mediados por bradiquinina.
EA200401319A1 (ru)	2005-04-28	Новые гетероциклические соединения, способы их получения и фармацевтические композиции, содержащие эти соединения, и их использование в медицине
CA2274063A1 (en)	1998-06-11	Substituted pyrimidine compounds and their use
ES2188909T3 (es)	2003-07-01	Nuevos derivados de cis-3,4-cromano utiles para la prevencion o tratamiento de sindromes o enfermedades relacionados con el estrogeno. os
BR0112123A (pt)	2003-05-06	Composto
ATE355287T1 (de)	2006-03-15	2-oxo-1,3,4-trihydrochinazolin derivative zur behandlung von zellproliferationskrankheiten
EP1314732A3 (en)	2004-01-02	Substituted pyrimidine compounds and their use
DE60218726D1 (de)	2007-04-19	Verwendung von 4-oxo-butansäure derivaten zur behandlung der entzündung
RU94019331A (ru)	1995-11-10	Конденсированные трициклические азотсодержащие гетероциклы, фармацевтическая композиция, способ лечения